DE69716474D1 - Thrombininhibitor-konjugate und endogene träger - Google Patents
Thrombininhibitor-konjugate und endogene trägerInfo
- Publication number
- DE69716474D1 DE69716474D1 DE69716474T DE69716474T DE69716474D1 DE 69716474 D1 DE69716474 D1 DE 69716474D1 DE 69716474 T DE69716474 T DE 69716474T DE 69716474 T DE69716474 T DE 69716474T DE 69716474 D1 DE69716474 D1 DE 69716474D1
- Authority
- DE
- Germany
- Prior art keywords
- thrombin
- thrombin inhibitor
- bloodstream
- activity
- compared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/674,315 US5840733A (en) | 1996-07-01 | 1996-07-01 | Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes |
PCT/IB1997/001093 WO1998000171A2 (en) | 1996-07-01 | 1997-06-30 | Conjugates of thrombin inhibitors and endogenes carriers |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69716474D1 true DE69716474D1 (de) | 2002-11-21 |
Family
ID=24706128
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69716474T Expired - Lifetime DE69716474D1 (de) | 1996-07-01 | 1997-06-30 | Thrombininhibitor-konjugate und endogene träger |
Country Status (9)
Country | Link |
---|---|
US (4) | US5840733A (de) |
EP (1) | EP0956049B1 (de) |
JP (1) | JP2000514795A (de) |
KR (1) | KR20000022371A (de) |
AT (1) | ATE226092T1 (de) |
CA (1) | CA2258516A1 (de) |
DE (1) | DE69716474D1 (de) |
IL (1) | IL127712A0 (de) |
WO (1) | WO1998000171A2 (de) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5840733A (en) * | 1996-07-01 | 1998-11-24 | Redcell, Canada, Inc. | Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes |
US7033765B1 (en) | 1997-02-20 | 2006-04-25 | Toronto Research Chemicals, Inc. | Site-specific drug delivery |
ATE296115T1 (de) * | 1997-02-20 | 2005-06-15 | David S Dime | Ortsspezifische arzneimittel verabreichung |
US6437092B1 (en) | 1998-11-06 | 2002-08-20 | Conjuchem, Inc. | Conjugates of opioids and endogenous carriers |
CA2301799C (en) * | 1997-11-07 | 2007-08-07 | Conjuchem, Inc. | Novel conjugates of opioids and endogenous carriers |
WO1999024075A2 (en) | 1997-11-07 | 1999-05-20 | Conjuchem, Inc. | Affinity markers for human serum albumin |
US6107489A (en) * | 1998-03-17 | 2000-08-22 | Conjuchem, Inc. | Extended lifetimes in vivo renin inhibitors |
US20030170250A1 (en) * | 1998-03-23 | 2003-09-11 | Ezrin Alan M. | Local delivery of long lasting therapeutic agents |
JP2002512640A (ja) * | 1998-03-23 | 2002-04-23 | コンジュケム,インコーポレーテッド | 持続性治療薬の局所送達 |
ES2347027T3 (es) | 1998-05-22 | 2010-10-22 | The Board Of Trustees Of The Leland Stanford Junior University | Moleculas bifuncionales y terapias basadas en las mismas. |
US6440417B1 (en) * | 1998-11-06 | 2002-08-27 | Conjuchem, Inc. | Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments |
GB9824632D0 (en) * | 1998-11-10 | 1999-01-06 | Celltech Therapeutics Ltd | Biological compounds |
US20090175821A1 (en) * | 1999-05-17 | 2009-07-09 | Bridon Dominique P | Modified therapeutic peptides with extended half-lives in vivo |
EA003922B1 (ru) * | 1999-05-17 | 2003-10-30 | Конджачем, Инк. | Продолжительно действующие инсулинотропные пептиды |
US7601691B2 (en) | 1999-05-17 | 2009-10-13 | Conjuchem Biotechnologies Inc. | Anti-obesity agents |
US6514500B1 (en) * | 1999-10-15 | 2003-02-04 | Conjuchem, Inc. | Long lasting synthetic glucagon like peptide {GLP-!} |
US20040266673A1 (en) * | 2002-07-31 | 2004-12-30 | Peter Bakis | Long lasting natriuretic peptide derivatives |
US6887470B1 (en) | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
DE19926154A1 (de) * | 1999-06-09 | 2000-12-14 | Ktb Tumorforschungs Gmbh | Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung |
CA2383559A1 (en) * | 1999-08-23 | 2001-03-01 | Polaris Pharmaceuticals, Inc. | Inhibitors of binding between proteins and macromolecular ligands |
EP1889639A3 (de) * | 1999-09-07 | 2008-04-09 | ConjuChem Biotechnologies Inc. | Verfahren und Zusammensetzungen zur Herstellung antineoplastischer Wirkstoffe von hoher Haltbarkeit |
US6706892B1 (en) | 1999-09-07 | 2004-03-16 | Conjuchem, Inc. | Pulmonary delivery for bioconjugation |
EP1212120A2 (de) * | 1999-09-07 | 2002-06-12 | Conjuchem, Inc. | Verwendungen und zusammensetzungen, welche succinimide oder maleimide derivaten von antineoplastischen wirkstoffen enthalten, zur herstellung antineoplastischer wirkstoffen |
US6887842B1 (en) | 1999-11-19 | 2005-05-03 | The Board Of Trustees Of The Leland Stanford Junior University | Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug |
US7220552B1 (en) | 1999-11-19 | 2007-05-22 | The Board Of Trustees Of The Leland Stanford Junior University | Bifunctional molecules and their use in the disruption of protein-protein interactions |
AU2044001A (en) | 1999-11-19 | 2001-05-30 | Board Of Trustees Of The Leland Stanford Junior University | Targeted bifunctional molecules and therapies based thereon |
EP1980572A1 (de) * | 2001-02-16 | 2008-10-15 | ConjuChem Biotechnologies Inc. | Glucagonartiges Peptid 2 (GLP-2) mit Langzeitwirkung für die Behandlung von Magendarmerkrankungen und -störungen |
US6923939B1 (en) * | 2001-07-05 | 2005-08-02 | Uop Llc | Heat activated membrane introduction apparatus and method for screening materials |
JP4458240B2 (ja) * | 2001-11-26 | 2010-04-28 | ジェネンテック インコーポレイテッド | カテーテル組成物とその用途 |
NZ541365A (en) * | 2002-12-27 | 2009-09-25 | Diobex Inc | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
US7655618B2 (en) | 2002-12-27 | 2010-02-02 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
CA2526907C (en) * | 2003-01-17 | 2012-11-13 | Advanced Proteome Therapeutics, Inc. | Tandem analyses of noncovalently driven effectors for modulatory mapping of activities of protein sites |
US7384970B2 (en) | 2003-03-24 | 2008-06-10 | Irm Llc | Inhibitors of cathepsin S |
US7109243B2 (en) | 2003-03-24 | 2006-09-19 | Irm Llc | Inhibitors of cathepsin S |
WO2004103270A2 (en) * | 2003-04-02 | 2004-12-02 | Suntory Pharmaceutical Research Laboratories Llc | Compounds and methods for treatment of thrombosis |
US7173051B2 (en) | 2003-06-13 | 2007-02-06 | Irm, Llc | Inhibitors of cathepsin S |
US7256207B2 (en) | 2003-08-20 | 2007-08-14 | Irm Llc | Inhibitors of cathepsin S |
US20050181513A1 (en) * | 2004-02-18 | 2005-08-18 | Viorica Lopez-Avila | Methods and compositions for assessing a sample by MAILDI mass spectrometry |
CA2564031A1 (en) * | 2004-04-23 | 2005-11-03 | Conjuchem Biotechnologies Inc. | Method for the purification of albumin conjugates |
RU2416393C2 (ru) * | 2005-09-01 | 2011-04-20 | Бакстер Интернэшнл Инк. | Препаративная форма аргатробана |
US8168592B2 (en) | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
WO2007053946A1 (en) | 2005-11-09 | 2007-05-18 | Conjuchem Biotechnologies Inc. | Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin |
CN101384623B (zh) * | 2005-12-22 | 2013-07-24 | 常山凯捷健生物药物研发(河北)有限公司 | 白蛋白与治疗剂的预成型偶联物的制备方法 |
CA2668347C (en) | 2006-11-07 | 2017-06-20 | Genentech, Inc. | Tissue plasminogen activator variant uses |
US20090099074A1 (en) * | 2007-01-10 | 2009-04-16 | Conjuchem Biotechnologies Inc. | Modulating food intake |
US8343511B2 (en) | 2008-02-08 | 2013-01-01 | Red Hill Biopharma Ltd. | Methods and compositions for treating inflammatory bowel disease |
US20090221637A1 (en) * | 2008-02-29 | 2009-09-03 | Baxter International Inc. | Solid-state salt argatroban formulations and methods for producing and using the same |
US7915290B2 (en) * | 2008-02-29 | 2011-03-29 | Baxter International Inc. | Argatroban formulations and methods for making and using same |
AU2012336036A1 (en) | 2011-11-07 | 2014-06-19 | Diakron Pharmaceuticals Inc. | An extended release formulation of a direct thrombin inhibitor |
Family Cites Families (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3622615A (en) * | 1968-11-06 | 1971-11-23 | Parke Davis & Co | N{11 -(p-tolylsulfonyl)-L-arginine esters |
US4131673A (en) * | 1974-11-08 | 1978-12-26 | Mitsubishi Chemical Industries, Limited | N2 -arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
US4093712A (en) * | 1974-11-08 | 1978-06-06 | Mitsubishi Chemical Industries Limited | N2 -arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
US4097472A (en) * | 1974-11-08 | 1978-06-27 | Mitsubishi Chemical Industries Limited | N2 -arylsulfonyl-l-argininamides and the pharmaceutically acceptable salts thereof |
US4140681A (en) * | 1974-11-08 | 1979-02-20 | Mitsubishi Chemical Industries, Limited | N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
US4097591A (en) * | 1974-11-08 | 1978-06-27 | Mitsubishi Chemical Industries Limited | N2 -arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
US4073913A (en) * | 1974-11-08 | 1978-02-14 | Mitsubishi Chemical Industries Limited | N2 -arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
US3978045A (en) * | 1973-08-13 | 1976-08-31 | Mitsubishi Chemical Industries Ltd. | N2 -dansyl-L-arginine derivatives, and the pharmaceutically acceptable acid addition salts thereof |
US4101653A (en) * | 1974-11-08 | 1978-07-18 | Mitsubishi Chemical Industries Limited | N2 -arylsulfonyl-argininamides and the pharmaceutically acceptable salts thereof |
US4133880A (en) * | 1974-11-08 | 1979-01-09 | Mitsubishi Chemical Industries Ltd. | N2 -Substituted-L-arginine derivatives and the pharmaceutically acceptable acid addition salts thereof |
US4104392A (en) * | 1974-11-08 | 1978-08-01 | Mitsubishi Chemical Industries Ltd. | N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof, and antithrombotic compositions and methods employing them |
US4168307A (en) * | 1974-11-08 | 1979-09-18 | Mitsubishi Chemical Industries Limited | N2 -Naphthalenesulfonyl-L-arginine derivatives, and the pharmaceutically acceptable acid addition salts thereof |
US4070457A (en) * | 1974-11-08 | 1978-01-24 | Mitsubishi Chemical Industries Ltd. | N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
US4066773A (en) * | 1974-11-08 | 1978-01-03 | Mitsubishi Chemical Industries Ltd. | N2 -arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
US4073916A (en) * | 1974-11-08 | 1978-02-14 | Mitsubishi Chemical Industries Limited | N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
US4096255A (en) * | 1974-11-08 | 1978-06-20 | Mitsubishi Chemical Industries Limited | N2 -naphthalenesulfonyl-L-argininamides, and pharmaceutical salts, compositions and methods |
US4018915A (en) * | 1976-01-05 | 1977-04-19 | Mitsubishi Chemical Industries Ltd. | N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
US4201863A (en) * | 1974-11-08 | 1980-05-06 | Mitsubishi Chemical Industries, Limited | N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
US4139529A (en) * | 1974-11-08 | 1979-02-13 | Mitsubishi Chemical Industries Limited | N2 -Naphthalenesulfonyl-L-arginine derivatives and the pharmaceutically acceptable acid addition salts thereof |
US4154828A (en) * | 1974-11-08 | 1979-05-15 | Mitsubishi Chemical Industries, Ltd. | N2 -Naphthalenesulfonyl-L-arginine derivatives, and the pharmaceutically acceptable acid addition salts thereof |
US4069318A (en) * | 1974-11-08 | 1978-01-17 | Mitsubishi Chemical Industries Ltd. | N2 -Alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
US4073914A (en) * | 1974-11-08 | 1978-02-14 | Mitsubishi Chemical Industries Limited | N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
US4069323A (en) * | 1974-11-08 | 1978-01-17 | Mitsubishi Chemical Industries Ltd. | N2 -substituted-L-arginine derivatives and the pharmaceutically acceptable acid addition salts thereof |
US4069329A (en) * | 1974-11-08 | 1978-01-17 | Mitsubishi Chemical Industries Limited | N2 -Naphthalenesulfonyl-L-arginine derivatives, and the pharmaceutically acceptable acid addition salts thereof |
US4125604A (en) * | 1974-11-08 | 1978-11-14 | Mitsubishi Chemical Industries Limited | N2-Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
US4055651A (en) * | 1974-11-08 | 1977-10-25 | Mitsubishi Chemical Industries Ltd. | N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
US4125619A (en) * | 1974-11-08 | 1978-11-14 | Mitsubishi Chemical Industries, Ltd. | N2 -naphthalenesulfonyl-L-arginine derivatives and the pharmaceutically acceptable acid addition salts thereof |
US4173630A (en) * | 1974-11-08 | 1979-11-06 | Mitsubishi Chemical Industries Limited | N2 Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
US4117127A (en) * | 1974-11-08 | 1978-09-26 | Mitsubishi Chemical Industries Ltd. | N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
US4041156A (en) * | 1974-11-08 | 1977-08-09 | Mitsubishi Chemical Industries Limited | N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
NL7512637A (nl) * | 1974-11-08 | 1976-05-11 | Mitsubishi Chem Ind | Werkwijze ter bereiding van een geneesmiddel, het aldus gevormde geneesmiddel en werkwijze voor de bereiding van actieve component. |
US4072757A (en) * | 1974-11-08 | 1978-02-07 | Mitsubishi Chemical Industries Limited | N2 alkoxynaphthylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
US4108986A (en) * | 1974-11-08 | 1978-08-22 | Mitsubishi Chemical Industries Limited | N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
US4046876A (en) * | 1974-11-08 | 1977-09-06 | Mitsubishi Chemical Industries Limited | N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
US4072744A (en) * | 1974-11-08 | 1978-02-07 | Mitsubishi Chemical Industries Limited | N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
US4069317A (en) * | 1974-11-08 | 1978-01-17 | Mitsubishi Chemical Industries Ltd. | N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
US4066759A (en) * | 1974-11-08 | 1978-01-03 | Mitsubishi Chemical Industries Limited | N2 -naphthalenesulfonyl-L-arginine derivatives, and the pharmaceutically acceptable acid addition salts thereof |
US4073891A (en) * | 1974-11-08 | 1978-02-14 | Mitsubishi Chemical Industries Limited | N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
US4073892A (en) * | 1974-11-08 | 1978-02-14 | Mitsubishi Chemical Industries Limited | N2 -alkoxynaphthylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
US4072743A (en) * | 1974-11-08 | 1978-02-07 | Mitsubishi Chemical Industries Limited | N2 -arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
US4055636A (en) * | 1974-11-08 | 1977-10-25 | Mitsubishi Chemical Industries Ltd. | N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
US3992530A (en) * | 1975-12-08 | 1976-11-16 | American Home Products Corporation | [D-2-(1,4-Cyclohexadienyl)gly]6 -des-gly10 -lrh nonapeptide amides |
US4036955A (en) * | 1976-07-22 | 1977-07-19 | Mitsubishi Chemical Industries Ltd. | N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
US4018913A (en) * | 1976-01-14 | 1977-04-19 | Mitsubishi Chemical Industries Ltd. | N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
US4071621A (en) * | 1976-01-14 | 1978-01-31 | Mitsubishi Chemical Industries Limited | N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
US4258192A (en) * | 1977-12-16 | 1981-03-24 | Mitsubishi Chemical Industries Limited | N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
IE48623B1 (en) * | 1978-08-31 | 1985-03-20 | Mitsubishi Chem Ind | Alpha-(n-arylsulfonyl-l-argininamides,processes for their preparation and pharmaceutical compositions containing these substances |
WO1982001873A1 (en) * | 1980-12-05 | 1982-06-10 | Takeda Chemical Industries Ltd | 1-sulfo-2-oxoazetidine derivatives and process for their preparation |
SE8203887D0 (sv) * | 1982-06-23 | 1982-06-23 | Kabivitrum Ab | Nya trombininhiberande foreningar |
JPS61112018A (ja) * | 1984-11-06 | 1986-05-30 | Mitsubishi Chem Ind Ltd | 線溶増強剤 |
PT84170B (pt) * | 1986-01-24 | 1989-03-30 | Sanofi Sa | Processo para a preparacao de derivados n alfa-substituidos das n alfa-aril-sulfonilaminoacil d-amidinofenil-alaninamidas |
ES2052517T3 (es) * | 1986-07-16 | 1994-07-16 | Eniricerche Spa | Analogos de tuftsina parcialmente retroinversos, metodo de preparacion de los mismos y composiciones farmaceuticas que los contienen. |
US5112615A (en) * | 1988-08-03 | 1992-05-12 | New England Deaconess Hospital Corporation | Soluble hirudin conjugates |
US5632991A (en) * | 1988-11-14 | 1997-05-27 | Brigham & Women's Hospital | Antibodies specific for E-selectin and the uses thereof |
EP0465556B1 (de) * | 1989-04-03 | 1995-06-28 | Centocor, Inc. | Blutplättchenspezifische immunokonjugate |
JPH04502769A (ja) * | 1989-04-10 | 1992-05-21 | オンコーゲン リミテッド パートナーシップ | オンコスタチンmを使用したヒト内皮細胞増殖およびエフェクター機能の制御法 |
EP0395918A3 (de) * | 1989-04-13 | 1991-10-23 | Vascular Laboratory, Inc. | Plasminogen-Aktivatorkomplex von reiner Pro-Urokinase, kovalent gebunden durch eine Disulfidbrücke an menschlichem Serumalbumin |
US5196404B1 (en) * | 1989-08-18 | 1996-09-10 | Biogen Inc | Inhibitors of thrombin |
US5240913A (en) * | 1989-08-18 | 1993-08-31 | Biogen, Inc. | Inhibitors of thrombin |
US5612034A (en) * | 1990-10-03 | 1997-03-18 | Redcell, Inc. | Super-globuling for in vivo extended lifetimes |
US5843440A (en) | 1990-10-03 | 1998-12-01 | Redcell Canada, Inc. | Cellular and serum protein anchors for modulating pharmacokinetics |
US5242810A (en) * | 1990-12-07 | 1993-09-07 | Biogen, Inc. | Bifunctional inhibitors of thrombin and platelet activation |
US5122615A (en) * | 1990-12-11 | 1992-06-16 | American Cyanamid Company | Process for the preparation of insecticidal, nematicidal and acaricidal 2-halo-3-substituted-5-arylpyrrole compounds |
DE4111394A1 (de) * | 1991-04-09 | 1992-10-15 | Behringwerke Ag | Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel |
DE4115468A1 (de) * | 1991-05-11 | 1992-11-12 | Behringwerke Ag | Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel als antikoagulantien |
US5458568A (en) * | 1991-05-24 | 1995-10-17 | Cortrak Medical, Inc. | Porous balloon for selective dilatation and drug delivery |
CA2074304C (en) * | 1991-08-02 | 1996-11-26 | Cyril J. Schweich, Jr. | Drug delivery catheter |
SE9102462D0 (sv) * | 1991-08-28 | 1991-08-28 | Astra Ab | New isosteric peptides |
US5635477A (en) * | 1991-09-30 | 1997-06-03 | The Dupont Merck Pharmaceutical Company | Cyclic compounds useful as inhibitors of platelet glycoprotein IIB/IIIA |
TW223629B (de) * | 1992-03-06 | 1994-05-11 | Hoffmann La Roche | |
US5506241A (en) * | 1992-03-18 | 1996-04-09 | Mitsubishi Chemical Corporation | Argatroban preparations for ophthalmic use |
FR2689130B1 (fr) * | 1992-03-30 | 1994-05-27 | Synthelabo | Derives de 1-[2 (arylsulfonylamino)ethyl-1-oxo] piperidine, leur preparation et leur application en therapeutique. |
US5371091A (en) * | 1992-08-31 | 1994-12-06 | Bristol-Myers Squibb Company | Heteroaromatic amine thrombin inhibitors |
FR2695562B1 (fr) * | 1992-09-11 | 1994-10-14 | Synthelabo | Utilisation d'un inhibiteur direct de la thrombine pour la fabrication d'un médicament à activité thrombolytique. |
EP0668875A4 (de) * | 1992-10-12 | 1999-05-26 | Agen Ltd | Auf blutgerinnsel gerichtetes antikoagulanz, verfahren zur herstellung desselben und zu seiner verwendung. |
US5371072A (en) * | 1992-10-16 | 1994-12-06 | Corvas International, Inc. | Asp-Pro-Arg α-keto-amide enzyme inhibitors |
US5583146A (en) * | 1992-12-02 | 1996-12-10 | Bristol-Myers Squibb Company | Heterocyclic thrombin inhibitors |
AU675981B2 (en) * | 1992-12-02 | 1997-02-27 | Bristol-Myers Squibb Company | Guanidinyl-substituted heterocyclic thrombin inhibitors |
EP0602290B1 (de) * | 1992-12-04 | 1999-08-25 | ConjuChem, Inc. | Antikörper-konjugiertes-Hepatitis B-Oberflächenantigen und dessen Verwendung |
US5332822A (en) * | 1992-12-24 | 1994-07-26 | Bristol-Myers Squibb Company | Heteroaromatic and thioheteroaromatic substituted sulfonamide thrombin inhibitors |
JPH06219948A (ja) * | 1993-01-25 | 1994-08-09 | Mitsubishi Kasei Corp | 抗トロンビン剤及びその製造方法 |
JPH06219949A (ja) * | 1993-01-25 | 1994-08-09 | Mitsubishi Kasei Corp | 抗トロンビン剤及びその製造方法 |
ATE181334T1 (de) * | 1993-02-12 | 1999-07-15 | Corvas Int Inc | Inhibitoren gegen thrombose |
AU5495194A (en) * | 1993-02-26 | 1994-09-01 | Becton Dickinson & Company | Flow through membrane nucleic acid hybridization assay |
FR2702220B1 (fr) * | 1993-03-03 | 1995-05-12 | Synthelabo | Dédoublement enzymatique de dérivés de 4-alkyl-2-pipéridine-carboxylate et utilisation des composés obtenus, comme intermédiaires de synthèse. |
DE69417087T2 (de) * | 1993-04-22 | 1999-07-15 | Senju Pharma Co | Wässrige Arzneizubereitungen enthaltend Argatroban und Cyclodextrin oder Coffein |
FR2710061B1 (fr) * | 1993-09-14 | 1995-12-29 | Synthelabo | Acides et chlorures d'acides 1,2,3, 4-tétrahydroquinoléine-8-sulfoniques, et leur utilisation comme intermédiaires de synthèse. |
DE4342154A1 (de) * | 1993-12-10 | 1995-06-14 | Behringwerke Ag | Amidinophenylalaninderivate, Verfahren zu deren Herstellung, deren Verwendung und diese enthaltende Mittel als Antikoagulantien |
FR2715566B1 (fr) * | 1994-02-03 | 1996-03-08 | Synthelabo | Solutions aqueuses concentrées d'argatroban. |
US5488037A (en) * | 1994-03-04 | 1996-01-30 | Eli Lilly And Company | Antithrombotic agents |
US5484772A (en) * | 1994-03-04 | 1996-01-16 | Eli Lilly And Company | Antithrombotic agents |
US5510330A (en) * | 1994-03-25 | 1996-04-23 | Boehringer Mannheim Gmbh | Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof. |
US5588962A (en) * | 1994-03-29 | 1996-12-31 | Boston Scientific Corporation | Drug treatment of diseased sites deep within the body |
US5561146A (en) * | 1994-06-10 | 1996-10-01 | Bristol-Myers Squibb Company | Modified guanidino and amidino thrombin inhibitors |
US5637599A (en) * | 1994-06-17 | 1997-06-10 | Corvas International, Inc. | Arginine mimic derivatives as enzyme inhibitors |
DE4424828A1 (de) * | 1994-07-14 | 1996-01-18 | Thomae Gmbh Dr K | Neue substituierte Arylsulfonamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
US5626562A (en) * | 1994-11-28 | 1997-05-06 | Devices For Vascular Intervention | Drug delivery catheter |
FR2728901B1 (fr) * | 1994-12-28 | 1997-03-28 | Sanofi Sa | Derives de phenyl-4-thiazoles substitues, procede pour leur preparation et compositions pharmaceutiques les contenant |
US5559150A (en) * | 1995-06-06 | 1996-09-24 | 3-Dimensional Pharmaceuticals, Inc. | N,N-disulfonylated aminobenzene carboxlic acids and the use thereof as thrombin inhibitors |
US5612378A (en) * | 1995-06-06 | 1997-03-18 | 3-Dimensional Pharmaceuticals, Inc. | Bis-arylsulfonylaminobenzamide derivatives and the use thereof as factor Xa inhibitors |
US5713853A (en) * | 1995-06-07 | 1998-02-03 | Interventional Innovations Corporation | Methods for treating thrombosis |
US5612369A (en) * | 1995-06-07 | 1997-03-18 | 3-Dimensional Pharmaceuticals, Inc. | Thrombin inhibitors |
US5840733A (en) * | 1996-07-01 | 1998-11-24 | Redcell, Canada, Inc. | Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes |
-
1996
- 1996-07-01 US US08/674,315 patent/US5840733A/en not_active Expired - Fee Related
-
1997
- 1997-06-30 CA CA002258516A patent/CA2258516A1/en not_active Abandoned
- 1997-06-30 WO PCT/IB1997/001093 patent/WO1998000171A2/en not_active Application Discontinuation
- 1997-06-30 JP JP10503954A patent/JP2000514795A/ja active Pending
- 1997-06-30 EP EP97937767A patent/EP0956049B1/de not_active Expired - Lifetime
- 1997-06-30 KR KR1019980710802A patent/KR20000022371A/ko not_active Application Discontinuation
- 1997-06-30 DE DE69716474T patent/DE69716474D1/de not_active Expired - Lifetime
- 1997-06-30 AT AT97937767T patent/ATE226092T1/de not_active IP Right Cessation
- 1997-06-30 IL IL12771297A patent/IL127712A0/xx unknown
-
1998
- 1998-07-01 US US09/108,534 patent/US5942620A/en not_active Expired - Fee Related
-
1999
- 1999-06-11 US US09/330,744 patent/US6087375A/en not_active Expired - Lifetime
-
2000
- 2000-06-22 US US09/599,379 patent/US6277863B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
KR20000022371A (ko) | 2000-04-25 |
WO1998000171A3 (en) | 1998-06-04 |
ATE226092T1 (de) | 2002-11-15 |
US6277863B1 (en) | 2001-08-21 |
EP0956049A2 (de) | 1999-11-17 |
US5840733A (en) | 1998-11-24 |
JP2000514795A (ja) | 2000-11-07 |
WO1998000171A2 (en) | 1998-01-08 |
US5942620A (en) | 1999-08-24 |
IL127712A0 (en) | 1999-10-28 |
EP0956049B1 (de) | 2002-10-16 |
CA2258516A1 (en) | 1998-01-08 |
US6087375A (en) | 2000-07-11 |
AU4028397A (en) | 1998-01-21 |
AU715746B2 (en) | 2000-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69716474D1 (de) | Thrombininhibitor-konjugate und endogene träger | |
Fontaine et al. | Long-term stabilization of maleimide–thiol conjugates | |
PT1112275E (pt) | Novos inibidores heteroaromaticos da frutose-1,6-bisfosfatase | |
DK1161452T3 (da) | Kovalent forbundne insulindimerer | |
BR9810465A (pt) | Inibidores da farnesiltransferase de proteìnas | |
WO1997029779A3 (en) | EGF-Genistein conjugates for the treatment of cancer | |
WO2003061577A8 (en) | Polyalkylene glycol with moiety for conjugating biologically active compound | |
ATE263579T1 (de) | Abgabe von polyethylene glycol-molekül- konjugaten aus abbaubarem hydrogel | |
TR200102603T2 (tr) | Antitümör aktiviteye sahip olan kamptotesin türevleri | |
MXPA04004026A (es) | Conjugados polimericos de inhibidores de la proteina quinasa c. | |
DE69920462D1 (de) | Verwendung von antikörper gegen aminophospholipide zur krebsbehandlung | |
PT988056E (pt) | Metodos e composicoes de factor tecidual para o tratamento da coagulacao e de tumores | |
NO20015584L (no) | Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling | |
BR0014378A (pt) | Derivados de ácido indolil-3-glioxìlico tendo propriedades terapeuticamente valiosas | |
EA200401622A1 (ru) | Способы лечения ангиогенеза, роста опухолей и метастазов | |
EA200200450A1 (ru) | Синтез и способы применения 9-замещенных производных гуанина | |
ATE455120T1 (de) | Derivate von kettenverzweigten lipophilen molekülen und deren verwendung | |
US20020155999A1 (en) | Method of using a porphyrin-like molecule conjugated with an anti-cancer drug for the treatment of cancer | |
ATE317703T1 (de) | Polymer-wirkstoff-konjugate zur behandlung von krebs | |
ATE339202T1 (de) | Verwendung von alpha-halogenacryloyl-distamycin derivaten zur herstellung eines medikaments zur behandlung von krebs | |
ATE211482T1 (de) | Selektive inhibitoren des faktors x, eine azepinonstruktur enthaltend | |
ATE240100T1 (de) | Verwendung von fc101 als hemmstoff der angiogenese zur behandlung von krebs und anderen angiogenen krankheiten | |
BR0014192A (pt) | Conjugados de corantes e anticorpos contra estruturas-alvo da angiogênese, para representação intra-operativa da margem de tumores | |
EP1520588A3 (de) | Verwendung von Antikörper gegen Aminophospholipide zur Krebsbehandlung | |
DE69807200D1 (de) | Inklusionskomplexe in waessriger loesung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8332 | No legal effect for de |